24/7 Wall Street
21 Jun 2026, 14:30 UTC · 1h ago
Pharma Momentum Fuels Johnson & Johnson's Path to Double-Digit Upside
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
21 Jun 2026, 14:30 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Johnson & Johnson raised its 2026 full-year sales guidance to a range of $100.3B to $101.3B and adjusted EPS to $11.45 to $11.65. — Upward revisions to annual guidance typically signal strong operational confidence and drive positive price action.
+0.60JNJ's oncology portfolio is seeing significant growth, with Darzalex up 22.5% and Tremfya up 68.3% in Q1. — Strong growth in high-margin oncology assets provides a primary catalyst for the company's bull case.
+0.50Stelara revenue crashed by nearly 60% in Q1 due to biosimilar competition. — A sharp decline in a major revenue-generating product creates a significant earnings headwind that the company must offset.
-0.40Continue reading
6 related stories
Search tags
Ongoing talc litigation remains a financial overhang, with $330 million in charges recorded in Q1. — Legal liabilities create unpredictable risks and non-recurring costs that can depress the stock's multiple.
The company is pursuing a potential spin-off of its DePuy Synthes orthopaedics business within an 18 to 24 month window. — Strategic separations can unlock shareholder value and improve the growth profile of the remaining entity.
+0.30Which stocks this story touches
The company received a BUY rating with strong oncology growth and raised guidance, despite talc litigation and Stelara revenue declines.
Reported Q1 2026 results that beat revenue expectations.
Noted for steady organic growth and a long streak of consecutive dividend increases.
Mentioned positively as a historical success story for a top analyst.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
42m ago
